Biotechnology company Flex Pharma Inc (Nasdaq:FLKS) on Friday announced positive voting response relating to its planned merger with Salarius Pharmaceuticals LLC.
Flex Pharma said that at its special meeting of stockholders, all proposals were approved with regard to its planned merger with Salarius Pharmaceuticals LLC.
In conjunction, Flex Pharma added that it will file a Form 8-K to disclose detailed voting results for each proposal and expects to complete the merger within the next week or two.
Salarius Pharmaceuticals LLC is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma. It has also received the US Food and Drug Administration's orphan drug designation and paediatric rare disease designation for Seclidemstat.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia